Is Vesugen FDA approved?
No. This profile records Vesugen as not FDA approved and for research use only.
MORE CONTEXT ›
Review the regulatory and source details on this page for the current context.
Cognitive CATEGORY
Vesugen
THE VESSEL PROTECTOR
A-7 Vascular Endothelium Bioregulator Peptide, KED
Vesugen is a synthetic tripeptide (Lys-Glu-Asp) that specifically targets the endothelium, the inner lining of your blood vessels. It reverses age-related declines in vascular elasticity, enhances nitric oxide production, and supports both cardiovascular and cognitive health by improving blood flow throughout the body.
Vesugen
Vesugen
Vesugen
Vesugen Evidence Snapshot
How these guides are reviewed
REGULATORY STATUS
Not FDA approved · research use only
DOSING GUIDANCE
Reviewed by our clinical team
LINKED EVIDENCE
1 research sources
CONTENT UPDATED
Aug 28, 2026
Dose and schedule recommendations shown below come from The Peptide App Clinical Team. Research links are provided so readers can inspect the supporting evidence directly. Review the sources.
Quick Answers About Vesugen
What dose does The Peptide App Clinical Team recommend for Vesugen?
Dose: 20 mg daily (oral/sublingual/subcutaneous).
MORE CONTEXT ›
Schedule: daily. Cycle: 4 weeks on, 12 weeks off. This is clinical-team guidance for reference and does not replace individualized instructions from a licensed clinician.
What research supports this Vesugen guide?
This guide links to 1 curated or current research sources.
MORE CONTEXT ›
Open the research section to inspect the source titles, publication details, study types, and available abstracts directly.
Studied Effects & Mechanisms
Endothelial Gene Activation
Upregulates eNOS, KLF2, VE-cadherin, and SIRT1 via epigenetic modification
Anti-Inflammatory
Suppresses NF-κB and STAT3 signaling, reducing adhesion molecules
Matrix Integrity
Upregulates elastin and collagen IV for vascular structure
People with hypertension or vascular stiffness
Those recovering from stroke or ischemic events
Anyone wanting to protect blood vessels during aging
People with cognitive decline related to poor circulation
Those with microvascular disease or diabetes
Vesugen Research
Live research temporarily unavailableThe live research feed did not return papers for this page. The curated references below remain available for crawlable source context.
RESEARCH REFERENCES